You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

CLORAZEPATE DIPOTASSIUM - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for clorazepate dipotassium and what is the scope of patent protection?

Clorazepate dipotassium is the generic ingredient in four branded drugs marketed by Able, Am Therap, Dash Pharms, Dava Pharms Inc, Gd Searle Llc, Purepac Pharm, Quantum Pharmics, Rising, Usl Pharma, Warner Chilcott, Watson Labs, Ajenat Pharms, Aurobindo Pharma, Aurolife Pharma Llc, Corepharma, Lederle, Novitium Pharma, Sun Pharm Inds Ltd, Taro, and Alra, and is included in sixty-two NDAs. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for clorazepate dipotassium. Seven suppliers are listed for this compound.

Summary for CLORAZEPATE DIPOTASSIUM
Drug Prices for CLORAZEPATE DIPOTASSIUM

See drug prices for CLORAZEPATE DIPOTASSIUM

Recent Clinical Trials for CLORAZEPATE DIPOTASSIUM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assistance Publique - Hôpitaux de ParisPhase 3
Ranbaxy Laboratories LimitedN/A

See all CLORAZEPATE DIPOTASSIUM clinical trials

Pharmacology for CLORAZEPATE DIPOTASSIUM
Drug ClassBenzodiazepine
Medical Subject Heading (MeSH) Categories for CLORAZEPATE DIPOTASSIUM

US Patents and Regulatory Information for CLORAZEPATE DIPOTASSIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle Llc CLORAZEPATE DIPOTASSIUM clorazepate dipotassium CAPSULE;ORAL 071729-001 Dec 18, 1987 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Warner Chilcott CLORAZEPATE DIPOTASSIUM clorazepate dipotassium TABLET;ORAL 071829-001 Mar 3, 1988 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Sun Pharm Inds Ltd CLORAZEPATE DIPOTASSIUM clorazepate dipotassium TABLET;ORAL 076911-002 Sep 29, 2004 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Taro CLORAZEPATE DIPOTASSIUM clorazepate dipotassium TABLET;ORAL 075731-001 Apr 27, 2000 AB RX No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Gd Searle Llc CLORAZEPATE DIPOTASSIUM clorazepate dipotassium CAPSULE;ORAL 071728-001 Dec 18, 1987 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CLORAZEPATE DIPOTASSIUM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ajenat Pharms TRANXENE clorazepate dipotassium TABLET;ORAL 017105-007 Approved Prior to Jan 1, 1982 ⤷  Subscribe ⤷  Subscribe
Ajenat Pharms TRANXENE clorazepate dipotassium CAPSULE;ORAL 017105-001 Approved Prior to Jan 1, 1982 ⤷  Subscribe ⤷  Subscribe
Ajenat Pharms TRANXENE SD clorazepate dipotassium TABLET;ORAL 017105-005 Approved Prior to Jan 1, 1982 ⤷  Subscribe ⤷  Subscribe
Ajenat Pharms TRANXENE clorazepate dipotassium TABLET;ORAL 017105-008 Approved Prior to Jan 1, 1982 ⤷  Subscribe ⤷  Subscribe
Ajenat Pharms TRANXENE clorazepate dipotassium TABLET;ORAL 017105-006 Approved Prior to Jan 1, 1982 ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

CLORAZEPATE DIPOTASSIUM Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Clorazepate Dipotassium

Introduction

Clorazepate dipotassium, marketed under the brand name Tranxene, is a benzodiazepine used for the management of anxiety disorders, short-term relief of anxiety symptoms, and as adjunctive therapy in the management of partial seizures and acute alcohol withdrawal. Here, we will delve into the market dynamics and financial trajectory of this drug.

Market Indications and Usage

Clorazepate dipotassium is indicated for several clinical uses, including the management of anxiety disorders, short-term relief of anxiety symptoms, adjunctive therapy in partial seizures, and symptomatic relief of acute alcohol withdrawal[2][3][5].

Competitive Landscape

The benzodiazepine market is competitive, with several other drugs available for similar indications. However, clorazepate dipotassium has a unique profile due to its rapid decarboxylation to nordiazepam, which provides a prolonged therapeutic effect. This differentiates it from other benzodiazepines and can influence its market position[2][5].

Regulatory Environment

The regulatory environment plays a crucial role in the market dynamics of clorazepate dipotassium. The drug is subject to strict regulations due to its potential for abuse, misuse, and addiction. Healthcare providers must carefully consider these risks and follow guidelines for prescribing and monitoring patients[2][3].

Supply Chain and Availability

Recent shortages, such as the one announced by Recordati Rare Diseases in 2022, can significantly impact the market dynamics and financial performance of clorazepate dipotassium. Such shortages can lead to increased costs for manufacturers to address the issue and may result in lost revenue due to unmet demand[1].

Financial Performance

The financial performance of clorazepate dipotassium is influenced by several factors, including sales volume, pricing, and competition. Given its niche but critical indications, the drug can generate significant revenue, especially in markets where it is widely prescribed.

Pricing Strategies

Pricing strategies for clorazepate dipotassium must balance the need for profitability with the need to ensure patient access. The drug's pricing is often influenced by regulatory approvals, reimbursement policies, and competition from generic or branded alternatives[3].

Generic Competition

The presence of generic versions of clorazepate dipotassium can impact its market share and financial performance. Generic competition often leads to lower prices, which can reduce the revenue generated by the branded version but may also increase overall market size due to greater affordability[2].

Research and Development

Continuous research and development are crucial for maintaining market position. Studies on long-term efficacy, safety, and potential new indications can help extend the drug's patent life and enhance its market value. For example, long-term studies in epileptic patients have shown continued therapeutic activity, which supports its use beyond initial indications[2][5].

Safety and Efficacy Concerns

Safety and efficacy concerns, such as the risk of abuse, misuse, and addiction, as well as potential withdrawal reactions, can affect the drug's market dynamics. These risks necessitate careful prescribing practices and ongoing monitoring, which can impact patient compliance and overall market performance[2][3].

Market Trends

Market trends in the pharmaceutical industry, such as the shift towards more targeted therapies and the increasing focus on mental health, can influence the demand for clorazepate dipotassium. Growing awareness of anxiety disorders and the need for effective treatments can drive market growth[2].

Geographical Market

The geographical market for clorazepate dipotassium varies, with different regions having different regulatory environments, healthcare systems, and patient needs. Understanding these regional differences is crucial for effective market strategy and financial planning.

Patient and Prescriber Education

Educating patients and prescribers about the benefits and risks of clorazepate dipotassium is essential for its successful market performance. This includes informing them about proper use, potential side effects, and the importance of gradual tapering to avoid withdrawal reactions[2][3].

Key Takeaways

  • Market Indications: Clorazepate dipotassium is used for anxiety disorders, partial seizures, and acute alcohol withdrawal.
  • Regulatory Environment: Strict regulations due to abuse and addiction risks.
  • Supply Chain: Shortages can impact market dynamics and financial performance.
  • Financial Performance: Influenced by sales volume, pricing, and competition.
  • Generic Competition: Affects market share and pricing.
  • Research and Development: Crucial for maintaining market position.
  • Safety and Efficacy Concerns: Impact patient compliance and market performance.
  • Market Trends: Growing awareness of mental health can drive demand.

Frequently Asked Questions

Q1: What are the primary indications for clorazepate dipotassium?

  • Clorazepate dipotassium is indicated for the management of anxiety disorders, short-term relief of anxiety symptoms, adjunctive therapy in partial seizures, and symptomatic relief of acute alcohol withdrawal[2][3][5].

Q2: What are the risks associated with clorazepate dipotassium?

  • The drug is associated with risks of abuse, misuse, and addiction, as well as potential withdrawal reactions. Concomitant use with opioids can lead to profound sedation, respiratory depression, coma, and death[2][3].

Q3: How does clorazepate dipotassium differ from other benzodiazepines?

  • Clorazepate dipotassium is rapidly decarboxylated to form nordiazepam, providing a prolonged therapeutic effect. This differentiates it from other benzodiazepines[2][5].

Q4: What impact do shortages have on the market dynamics of clorazepate dipotassium?

  • Shortages can lead to increased costs for manufacturers and result in lost revenue due to unmet demand. They also affect patient access and compliance[1].

Q5: How does generic competition affect the market performance of clorazepate dipotassium?

  • Generic competition can reduce the market share and revenue of the branded version but may increase overall market size due to greater affordability[2].

Cited Sources

  1. Recordati Rare Diseases. Health-Care Provider Letter - Tranxene - March 2022. [PDF]
  2. DailyMed. Label: CLORAZEPATE DIPOTASSIUM tablet.
  3. FDA. Tranxene® T-TAB® Tablets (clorazepate dipotassium tablets, USP).
  4. INCHEM. Clorazepate dipotassium (PIM 327).
  5. FDA. Tranxene (clorazepate dipotassium) tablets label. [PDF]

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.